Clinical Trial Update: A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy [Phase 1, Phase 2]

View source ↗

Summary

Genmab's GEN1053 antibody study in malignant solid tumors (Phase 1/2) was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• GEN1053

Snippet

Sponsor: Genmab | Conditions: Solid Tumor, Adult | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-04-22